157 related articles for article (PubMed ID: 25779358)
1. CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer.
Go SI; Ko GH; Lee WS; Kim RB; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2016 Jan; 48(1):142-52. PubMed ID: 25779358
[TBL] [Abstract][Full Text] [Related]
2. The Use of CD44 Variant 9 and Ki-67 Combination Can Predicts Prognosis Better Than Their Single Use in Early Gastric Cancer.
Go SI; Ko GH; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Cancer Res Treat; 2019 Oct; 51(4):1411-1419. PubMed ID: 30913874
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression.
Yasui W; Kudo Y; Naka K; Fujimoto J; Ue T; Yokozaki H; Tahara E
Int J Oncol; 1998 Jun; 12(6):1253-8. PubMed ID: 9592182
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of Ki-67 in patients with gastric cancer-the importance of depth of invasion and histologic differentiation.
Ko GH; Go SI; Lee WS; Lee JH; Jeong SH; Lee YJ; Hong SC; Ha WS
Medicine (Baltimore); 2017 Jun; 96(25):e7181. PubMed ID: 28640099
[TBL] [Abstract][Full Text] [Related]
5. CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence.
Hirata K; Suzuki H; Imaeda H; Matsuzaki J; Tsugawa H; Nagano O; Asakura K; Saya H; Hibi T
Br J Cancer; 2013 Jul; 109(2):379-86. PubMed ID: 23778530
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD44 variant 9 induces chemoresistance of gastric cancer by controlling intracellular reactive oxygen spices accumulation.
Jogo T; Oki E; Nakanishi R; Ando K; Nakashima Y; Kimura Y; Saeki H; Oda Y; Maehara Y; Mori M
Gastric Cancer; 2021 Sep; 24(5):1089-1099. PubMed ID: 33963958
[TBL] [Abstract][Full Text] [Related]
7. CD44 variant 9 expression as a predictor for gastric cancer recurrence: immunohistochemical and metabolomic analysis of surgically resected tissues.
Yamakawa Y; Kusuhara M; Terashima M; Kinugasa Y; Sugino T; Abe M; Mochizuki T; Hatakeyama K; Kami K; Yamaguchi K
Biomed Res; 2017; 38(1):41-52. PubMed ID: 28239031
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of osteopontin and CD44v9 in gastric cancer.
Ue T; Yokozaki H; Kitadai Y; Yamamoto S; Yasui W; Ishikawa T; Tahara E
Int J Cancer; 1998 Apr; 79(2):127-32. PubMed ID: 9583725
[TBL] [Abstract][Full Text] [Related]
9. Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.
Hagiwara M; Kikuchi E; Kosaka T; Mikami S; Saya H; Oya M
Urol Oncol; 2016 Aug; 34(8):337.e19-26. PubMed ID: 27133224
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
Kodama H; Murata S; Ishida M; Yamamoto H; Yamaguchi T; Kaida S; Miyake T; Takebayashi K; Kushima R; Tani M
Br J Cancer; 2017 Jan; 116(2):186-194. PubMed ID: 27931044
[TBL] [Abstract][Full Text] [Related]
11. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance].
Xie JW; Huang CM; Zheng CH; Li P; Wang JB; Lin JX; Lu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1107-12. PubMed ID: 24277411
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting xCT Improves 5-Fluorouracil Resistance of Gastric Cancer Induced by CD44 Variant 9 Expression.
Miyoshi S; Tsugawa H; Matsuzaki J; Hirata K; Mori H; Saya H; Kanai T; Suzuki H
Anticancer Res; 2018 Nov; 38(11):6163-6170. PubMed ID: 30396933
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
14. CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer.
Choi ES; Kim H; Kim HP; Choi Y; Goh SH
Sci Rep; 2017 Jul; 7(1):4930. PubMed ID: 28694503
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors of lymph node-negative metastasis gastric cancer].
Sun D; Xu H; Huang J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):190-194. PubMed ID: 28226354
[TBL] [Abstract][Full Text] [Related]
16. Impact of Truncated
Moreira IB; Pinto F; Gomes C; Campos D; Reis CA
Cells; 2020 Jan; 9(2):. PubMed ID: 31973075
[TBL] [Abstract][Full Text] [Related]
17. CD44 overexpression related to lymph node metastasis and poor prognosis of pancreatic cancer.
Liu Y; Wu T; Lu D; Zhen J; Zhang L
Int J Biol Markers; 2018 Aug; 33(3):308-313. PubMed ID: 29683068
[TBL] [Abstract][Full Text] [Related]
18. In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
Mashima T; Iwasaki R; Kawata N; Kawakami R; Kumagai K; Migita T; Sano T; Yamaguchi K; Seimiya H
Br J Cancer; 2019 Nov; 121(10):846-856. PubMed ID: 31607750
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CD44 in human colon cancer and gastric cancer: Evidence from bioinformatic analyses.
Xia P; Xu XY
Oncotarget; 2016 Jul; 7(29):45538-45546. PubMed ID: 27323782
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CD44v9 expression in human cancers: A systematic review and meta-analysis.
Zeng L; Chen Y; Chen L; Tang C
Medicine (Baltimore); 2020 Jul; 99(30):e20428. PubMed ID: 32791660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
